|Articles|July 20, 2018

FDA Issues Warning Statement About Contaminated Illegal Synthetic Cannabinoid Products

The FDA released a statement this week about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum.

The U.S. Food and Drug Administration (FDA) released a statement this week (1) about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum, a very long-acting anticoagulant commonly used in rat poison. According to the statement, these unapproved products are being sold in convenience stores and gas stations as substitutes for cannabis under names such as “K2” and “Spice.”

The statement came from Commissioner Scott Gottlieb, MD, Peter Marks, MD, PhD, who is the director for the Center for Biologics Evaluation and Research, and Janet Woodcock, MD, who is the director of the Center for Drug Evaluation and Research. They stressed that the presence of brodifacoum in these illegal and unregulated products poses severe health risks because it can cause severe bleeding. They also explained that in recent months, hundreds of individuals in about 10 states (many in the Midwest) have been hospitalized after experiencing such complications.

“Today, we’re joining together to send a strong warning to anyone who may use synthetic marijuana products that these products can be especially dangerous as a result of the seemingly deliberate use of brodifacoum in these illegal products,” they said in the statement.

The statement also stressed that the use of these illegal products poses significant public health concerns for both individuals who use them and the U.S. blood supply because there is the potential for contamination of blood products donated by those individuals who have used these substances...

For more information, please read the full press release.

References:

  1. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm614027.htm?utm_campaign=07192018_Statement_FDA%20warns%20of%20significant%20health%20risks%20from%20synthetic%20cannabinoids&utm_medium=email&utm_source=Eloqua

Related to this article

2025 Medical Cannabis Roundup
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Image | adobe.stock/Stock Rocket
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
Manipulating Cannabis Genetics: Pulling Levers to Increase  Phytochemical Composition
Cannabis genetics fundamentally dictate the plant's potential for chemical signatures, including cannabinoid and terpene profiles, and physical traits, such as yield. Cultivators use selective techniques, such as "stacking," to enhance specific compounds. Ultimately, successful cultivation involves balancing superior genetics with environmental "levers" to optimize gene expression and create targeted strains.
Image | adobe.stock/Maksim Kabakou
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!